Most favored nation drug pricing hits an undisclosed 2028 cliff
Twenty-six companies now cover 89% of the branded drug market under voluntary MFN agreements, but SEC filings show three-year terms with sunset dates buyers cannot see.
Most favored nation drug pricing has moved from policy experiment to market default. Nine more companies signed agreements at an Oval Office event on Aug. 31, 2026, bringing participation to 26 and pushing claimed coverage to 89% of the branded drug market. What almost no one has modeled is the other side of the arithmetic: these are voluntary contracts with three-year terms, and the earliest ones start lapsing in 2028.
STAT review of SEC filings (Feb. 27, 2026); AP / White House (Aug. 31, 2026). Middle figure is arithmetic (26 total minus 9 announced Aug. 31), not a separately reported number.
| Value (companies) | Signatories |
|---|---|
| Late Feb. 2026 | 16 companies |
| Pre-Aug. 31, 2026 (derived) | 17 companies |
| Aug. 31, 2026 | 26 companies |
How MFN reached near-total market coverage in under two years
The Aug. 31 announcement added Alcon and Astellas Pharma among nine new signatories, according to TIME and the Associated Press. A White House fact sheet put coverage at 89% of the branded drug market, with President Trump citing roughly 90% of prescription drugs. Bloomberg had pre-reported the biotech round days earlier, and BioPharma Dive framed the latest wave as mid-cap biotechs entering the Medicaid low-price model that large-cap manufacturers accepted first.
The mechanics are consistent across the deals as publicly described. Every state Medicaid program gains access to MFN prices, which are pegged largely to prices paid in European markets. Select MFN prices also route to TrumpRx.gov, a cash-pay channel where patients transact outside insurance entirely. That second element is easy to underweight, and it is the one most likely to reshape channel economics for payers and health systems.
Expiration is not a single policy event. It is a rolling, contract-by-contract series of decisions that buyers cannot see coming.
The three-year term nobody has priced in
In February 2026, STAT reviewed SEC filings from what were then 16 signatories and found three-year terms for at least some companies, with many other terms unreleased. That means the earliest agreements begin expiring in 2028, and the wave that signed in 2026 carries sunset dates into 2029. Because the deals are voluntary and largely confidential, expiration is not a single policy event. It is a rolling, contract-by-contract series of decisions.
This creates an unusual forecasting problem. Medicaid programs, 340B covered entities and commercial payers are now transacting against a benchmark whose duration they cannot verify. A state Medicaid director building a 2029 pharmacy budget has no reliable way to know which molecules retain MFN pricing and which revert. Neither does a health system pharmacy leader modeling 340B savings, or a plan actuary setting rebate assumptions.
Margin absorption suggests the near term is stable
Evidence so far points to manufacturers absorbing rather than passing through the impact. Johnson & Johnson guided 2026 profit above Wall Street estimates despite both tariff exposure and the pricing agreements, per Reuters reporting cited in Health Affairs. For diversified large caps, MFN concessions on Medicaid volume appear manageable inside a broad portfolio.
The exposure is asymmetric further down the market cap. Mid-cap biotechs with narrow portfolios have no cushion, and their net-price forecasts now hinge on a benchmark with an undisclosed end date. Health Affairs also notes that MFN designs exert upward pressure on ex-US prices toward parity, and warns that the United States lacks the health technology assessment infrastructure to define when MFN has actually worked. Absent that, success will be judged by headline coverage percentages rather than net outcomes.
Three exposures for commercial and market access teams
First, net-price forecasting. Launch pricing decisions for 2027 through 2029 are being set against a Medicaid floor that may reset when contracts lapse. Teams should build dual scenarios rather than treating MFN as permanent structure.
Second, best-price interaction. MFN resets the Medicaid floor, which pulls through to 340B ceiling prices and Medicaid best-price calculations. Reversion in 2028 or 2029 would move those figures again, in the opposite direction, with downstream effects on covered-entity margins.
Third, channel conflict. When TrumpRx cash-pay pricing sits below plan-negotiated rates, patient steering behavior changes and rebate math weakens. For payers and health systems, a cash channel priced under the plan benchmark is not a marketing curiosity. It is a leakage pathway that erodes the volume commitments underpinning formulary contracts.
What healthcare leaders should ask before the 2027 planning cycle
The practical step is disclosure discipline. Pharma commercial teams should know their own expiration dates and stress-test portfolio economics for both renewal and lapse. Payers and health systems should press for term visibility in contracting conversations, because the absence of a published sunset schedule is now a material planning gap rather than a technicality.
Peak coverage and a hidden cliff are arriving together. Organizations that treat 89% coverage as a stable operating environment will be the ones caught renegotiating in the same quarter their benchmark disappears.
